NCT06113328: An ongoing trial by Merck Sharp & Dohme LLC
This trial is ongoing. It must report results 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06113328 |
|---|---|
| Title | A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Non-Segmental Vitiligo |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 27, 2023 |
| Completion date | March 20, 2025 |
| Required reporting date | March 20, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |